||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Midatech Pharma Share Discussion Threads
Showing 176 to 198 of 200 messages
|Placing @110p to raise £15mm|
|Not able to buy any more at the moment... Can sell though.... thought that the MM's had to offer at least some (tried a 50 quid test purchase and no luck). Is summit about to happen or have the MM's gone into a no sell mode... Just peeved as I also had the same result yesterday with a different broker.....
Edit 6/10 ... Success ... a few more added. Dunno what was going on the past couple of days..|
|A test, sorry.....|
|And there is currently another board too started by the avatar, dice1950, on 10 Aug '16 where a few people have already contributed, and a header as well:
This thread has a more useful header.|
|Be rather helpful if the funding options were resolved sooner rather than later.|
|Tx sophie - appreciated.|
|New video at Proactive Investors is here: http://tinyurl.com/gvdf4q2|
|going nowhere till fundraising is out of the way|
|Panmure reiterate their 380p target on this one....|
|results + fundraising|
|L2 - demand is strong and not much stock on offer. At the best bid/ask it's 4k v only 1k, with totals of only 8k shrs each side, spread over 6mm's(!), so some show only 1000 shrs.
No wonder share price moves nicely, on buying.
Woodford 19.98% here. fwiw.
|Looks as if the share price is on a bit of a roll|
|Maybe put the link above in the header dice?
All - note that it is two shares for one in the US.
So $4.40 (using www.xe.com/UCC) is converted to £3.33. Divide that by two and you get the equivalent UK price - about £1.67.
So currently cheaper to buy in the UK.|
|Shooting up in the US this afternoon:
|so it will need a rights issue in 2016 then, ouch!!!|
|Tx jambo - appreciated.
|Singers and Panmure updates on research tree:
"This morning’s trading H1 update indicates revenue in line with our expectations. We continue to believe that Midatech is at an interesting juncture, with the FDA filing of Q-Octreotide (a long-acting formulation of somatostatin) expected in the second half of the year and clinical trials for the company’s glioblastoma programme MTR103 due to commence in 2017e. We also continue to expect the group’s US speciality pharma operations to be cash generative from 2017e on a stand-alone basis." - Singers
"Trading and revenues for the first half are in-line with updated expectations following positive guidance within the company’s 2015 results statement and we maintain our full-year forecasts. First-half revenues are expected to be £3.80m (1H15 £0.32m). It has been a tremendously busy period for Midatech both in terms of pipeline development and in terms of commercial activities – we remind investors, particularly, of the US launch of Zuplenz in April – and we consider the gap between our target price and the current share price unduly discounts the value opportunity." - Panmure|
|should be cash generative by 2017 according to Singers|
|up 25% now!|
|running out of cash|
|Midatech Pharma (MTPH) shares surge on strong sales
more progress was expected
09:17 10 Aug 2016
|~~ADVFN*MODERATEDIsn't it running out of cash|